Sign In
Buy NAVB
$0.0001
+0 (+0%)
At Close: Dec 30, 2025
Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down
05:09pm, Thursday, 13'th Jul 2023
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an
Navidea Biopharmaceuticals rejects ProPhase Labs offer
09:44am, Friday, 30'th Jun 2023
Navidea Biopharmaceuticals Inc. NAVB, -2.38% announced Friday that it had rejected an unsolicited ProPhase Labs Inc. PRPH, +0.08% offer for certain Navidea assets, saying the proposal undervalues Navi
Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets
09:16am, Friday, 30'th Jun 2023
DUBLIN, Ohio--(BUSINESS WIRE)--Following the Company's Fix, Fund, Propel approach, the proposal substantially undervalues Navidea and is not in the best interests of stockholders.
Navidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common Stock
04:54pm, Friday, 16'th Jun 2023
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an
Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment
01:52pm, Friday, 16'th Jun 2023
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment.
Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
04:00pm, Wednesday, 07'th Jun 2023
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update.
Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice
05:54pm, Friday, 02'nd Jun 2023
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an
Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L.
05:53pm, Thursday, 01'st Jun 2023
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L. Cappello Steps Down.
Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market
06:30pm, Monday, 22'nd May 2023
DUBLIN, Ohio--(BUSINESS WIRE)--New Existing Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market.
Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer
05:35pm, Thursday, 11'th May 2023
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer.
Navidea Biopharmaceuticals, Inc. (NAVB) Q4 2022 Earnings Call Transcript
10:44pm, Tuesday, 21'st Mar 2023
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB ) Q4 2022 Earnings Conference Call March 22, 2023 5:00 PM ET Company Participants Michael Rosol - SVP & Chief Medical Officer Erika Eves - VP, Finance & Adm
Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
06:39pm, Tuesday, 03'rd Jan 2023 Benzinga
Gainers
Horizon Global Corporation (NYSE: HZN) shares surged 341% to $1.7161 after the company announced it will be acquired by First Brands Group.
Jasper Therapeutics, Inc. (NASDAQ: JSPR) gained 257
Why Silo Pharma Shares Are Trading Higher By Around 64%? Here Are 46 Stocks Moving In Friday's Mid-Day Session
05:28pm, Friday, 30'th Dec 2022 Benzinga
Gainers
Dermata Therapeutics, Inc. (NASDAQ: DRMA) shares jumped 121% to $0.4428 after the company requested to withdraw its registration on Form S-1 and said it does not intend to pursue the contempl
Navidea Biopharmaceuticals, Inc. (NAVB) Q3 2022 Earnings Call Transcript
08:49pm, Tuesday, 15'th Nov 2022
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB ) Q3 2022 Earnings Conference Call November 15, 2022 5:00 PM ET Company Participants Michael Rosol – Chief Medical Officer Erika Eves – Vice President-F
Navidea Biopharmaceuticals to Host Third Quarter 2022 Earnings Conference Call and Business Update
07:30am, Friday, 04'th Nov 2022
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an
